Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Jill U Adams"'
Autor:
Jill U. Adams
Publikováno v:
Science. 350:26-28
Ecologist Aram Calhoun forges creative alliances in her quest to protect ephemeral vernal pools.
Autor:
Jill U. Adams
Publikováno v:
Science. 321:269-276
European research institutions seek to diversify funding sources as well as their work force
Autor:
Jill U. Adams
Publikováno v:
Science. 319:831-836
Nationwide and institution-sized surveys show a leaky pipeline partially patched, but the reservoir still far from full.
Autor:
Jill U. Adams
Publikováno v:
Science. 318:1315-1318
Complex scientific problems and socially relevant issues are challenging scientists to find new ways to integrate knowledge from multiple and disparate fields. Increasingly, collaborative approaches are changing the way science is done.
Autor:
Jill U. Adams
Publikováno v:
Science. 317:1942-1946
In the same period of time it takes to earn a Ph.D., budding scientists can experiment with a wide variety of educational paths and career tracks-and discover what they really want to do. Read the Feature (Full-Text HTML) [Read the Feature (PDF)][1]
Autor:
Jill U. Adams
Publikováno v:
Nature. 527(7578)
Technology is allowing researchers to generate vast amounts of information about tumours. The next step is to use this genomic data to transform patient care.
Autor:
Jill U. Adams
Publikováno v:
Nature Biotechnology. 29:474-476
Autor:
Jill U, Adams
Publikováno v:
Scientific American. 311(3)
Autor:
Pamela D. Butler, Erica Duncan, Toby R Efferen, Stephen Gonzenbach, John Rotrosen, Burt Angrist, Jill U Adams, Sandor Szilagyi, Subhajit Chakravorty
Publikováno v:
Neuropsychopharmacology. 22:89-96
Chronic cocaine use has been shown to produce neurochemical alterations which persist after acute withdrawal. This study assessed the effects of cocaine use on the acoustic startle response and sensorimotor gating using prepulse inhibition (PPI) of s
Autor:
Jill U Adams
Publikováno v:
Nature Biotechnology. 27:309-311
A gout drug has been approved by the FDA, the first in 40 years, with three more in the wings. What accounts for this sudden slew of gout therapies? Jill U. Adams investigates.